BIOAGE LABS INC (BIOA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BIOA • US09077V1008

20.1 USD
+1.11 (+5.85%)
At close: Feb 2, 2026
20.1 USD
0 (0%)
After Hours: 2/2/2026, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, BIOA scores 3 out of 10 in our fundamental rating. BIOA was compared to 191 industry peers in the Pharmaceuticals industry. BIOA has a great financial health rating, but its profitability evaluates not so good. BIOA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • BIOA had negative earnings in the past year.
  • In the past year BIOA has reported a negative cash flow from operations.
BIOA Yearly Net Income VS EBIT VS OCF VS FCFBIOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • BIOA has a Return On Assets (-24.84%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -27.32%, BIOA is in the better half of the industry, outperforming 63.35% of the companies in the same industry.
Industry RankSector Rank
ROA -24.84%
ROE -27.32%
ROIC N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOA Yearly ROA, ROE, ROICBIOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400

1.3 Margins

  • BIOA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOA Yearly Profit, Operating, Gross MarginsBIOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for BIOA has been increased compared to 1 year ago.
  • Compared to 1 year ago, BIOA has an improved debt to assets ratio.
BIOA Yearly Shares OutstandingBIOA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
BIOA Yearly Total Debt VS Total AssetsBIOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • BIOA has an Altman-Z score of 14.34. This indicates that BIOA is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of BIOA (14.34) is better than 83.77% of its industry peers.
  • There is no outstanding debt for BIOA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.34
ROIC/WACCN/A
WACCN/A
BIOA Yearly LT Debt VS Equity VS FCFBIOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 11.87 indicates that BIOA has no problem at all paying its short term obligations.
  • BIOA's Current ratio of 11.87 is fine compared to the rest of the industry. BIOA outperforms 79.58% of its industry peers.
  • BIOA has a Quick Ratio of 11.87. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 11.87, BIOA is doing good in the industry, outperforming 79.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.87
Quick Ratio 11.87
BIOA Yearly Current Assets VS Current LiabilitesBIOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for BIOA have decreased by -6.13% in the last year.
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BIOA will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.53% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.51%
EPS Next 2Y28.05%
EPS Next 3Y17.53%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOA Yearly Revenue VS EstimatesBIOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2032 2033 10M 20M 30M 40M 50M
BIOA Yearly EPS VS EstimatesBIOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • BIOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BIOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOA Price Earnings VS Forward Price EarningsBIOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOA Per share dataBIOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BIOA's earnings are expected to grow with 17.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.05%
EPS Next 3Y17.53%

More info and screens

0

5. Dividend

5.1 Amount

  • BIOA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOAGE LABS INC

NASDAQ:BIOA (2/2/2026, 8:00:01 PM)

After market: 20.1 0 (0%)

20.1

+1.11 (+5.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-18
Inst Owners67.3%
Inst Owner Change-1.31%
Ins Owners3.64%
Ins Owner Change-11.19%
Market Cap720.79M
Revenue(TTM)5.92M
Net Income(TTM)-75.79M
Analysts78
Price Target12.24 (-39.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.16%
Min EPS beat(2)-22.35%
Max EPS beat(2)6.02%
EPS beat(4)3
Avg EPS beat(4)6%
Min EPS beat(4)-22.35%
Max EPS beat(4)33.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)201.02%
Min Revenue beat(2)94.32%
Max Revenue beat(2)307.71%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)50%
EPS NQ rev (1m)0.27%
EPS NQ rev (3m)-18.14%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)37.56%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)52.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 121.82
P/FCF N/A
P/OCF N/A
P/B 2.6
P/tB 2.6
EV/EBITDA N/A
EPS(TTM)-3.49
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-1.65
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS0.17
BVpS7.74
TBVpS7.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.84%
ROE -27.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 331.41%
Cap/Sales 10.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.87
Quick Ratio 11.87
Altman-Z 14.34
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.64%
EPS Next Y71.51%
EPS Next 2Y28.05%
EPS Next 3Y17.53%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.96%
EBIT Next 3Y-16.92%
EBIT Next 5YN/A
FCF growth 1Y-38.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.9%
OCF growth 3YN/A
OCF growth 5YN/A

BIOAGE LABS INC / BIOA FAQ

What is the ChartMill fundamental rating of BIOAGE LABS INC (BIOA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIOA.


Can you provide the valuation status for BIOAGE LABS INC?

ChartMill assigns a valuation rating of 0 / 10 to BIOAGE LABS INC (BIOA). This can be considered as Overvalued.


Can you provide the profitability details for BIOAGE LABS INC?

BIOAGE LABS INC (BIOA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BIOA stock?

The Earnings per Share (EPS) of BIOAGE LABS INC (BIOA) is expected to grow by 71.51% in the next year.